# An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

> **NCT01472003** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABT-806
- **DRUG:** ABT-806i

## Key facts

- **NCT ID:** NCT01472003
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472003, "An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01472003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*